NCI Pediatric In Vivo Testing Program Coordinating Center (U24 Clinical Trial Not Allowed)

The summary for the NCI Pediatric In Vivo Testing Program Coordinating Center (U24 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

NCI Pediatric In Vivo Testing Program Coordinating Center (U24 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) is for a Coordinating Center for the NCI Pediatric in Vivo Testing Program (henceforth termed the Ped-In Vivo-TP). The main goal for the Ped-InVivo-TP is to use genomically-characterized pediatric cancer models to develop a rigorous preclinical testing system to generate reliable data that can be used to inform new agent prioritization decisions for childhood cancers. The Ped-In Vivo-TP has two parts: a) research teams for in vivo testing to determine the activity of pediatric anticancer drug candidates, supported under RFA-CA-20-037); and b) a Coordinating Center (RFA-CA-20-041, this FOA). The Ped-InVivo-TP is envisioned as a way for NCI to support the Foundation for the National Institutes of Health (FNIH)-organized Public-Private Partnership (PPP) for pediatric preclinical testing. The PPP is being developed to accelerate the pace and to broaden the scope of pediatric preclinical testing of agents being developed for adult cancer indications. Pharmaceutical companies and representatives of regulatory agencies will also participate in the PPP. The Program Director(s)/Principal Investigator(s) [PD(s)/PI(s)] of the Ped-InVivo-TP Research Teams and Coordinating Center will be expected to serve on the Scientific Advisory Committee (SAC) of the FNIH PPP and will contribute to the SAC with regards to the research opportunities in their areas of expertise. This FOA invites applications for the Ped-InVivo-TP Coordinating Center. The Ped-InVivo-TP Coordinating Center will be responsible for integrating the activities of the individual Ped-InVivo-TP Research Teams to create a functional collaboration for pediatric preclinical testing. Specifically, the Ped-InVivo-TP Coordinating Center will be responsible for the following: 1) Administrative and logistical coordination; 2) Data management, statistical, and bioinformatics support; and 3) Scientific coordination and s

Federal Grant Title:	NCI Pediatric In Vivo Testing Program Coordinating Center (U24 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-20-041
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.395
CFDA Descriptions:	Information not provided
Current Application Deadline:	November 9th, 2020
Original Application Deadline:	November 9th, 2020
Posted Date:	August 25th, 2020
Creation Date:	August 25th, 2020
Archive Date:	December 15th, 2020
Total Program Funding:
Maximum Federal Grant Award:	$500,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	August 26th, 2020

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-041.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...; • Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical...; • Single Source: Pediatric Early Phase Clinical Trials Network (PEP-CTN; UM1 Clinical Trial ...; • Assay development and screening for discovery of chemical probes, drugs or immunomodulator...; • Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed); • Breast and Prostate Cancer Data Quality and Patterns of Care Study; • Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults; • National Cooperative Drug Discovery Groups for Cancer
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...